This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Intellect Neurosciences Issues Letter To Shareholders

NEW YORK, March 29, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Dear Shareholder,

I would like to take this opportunity to update you briefly regarding my recent trip to Europe, which included 27 meetings in 10 days! The vast majority of these meetings had to do with the strategic plan I outlined in my letter to you of February 13, 2013: namely, to move forward aggressively with our CONJUMAB-A and tau immunotherapy programs, which have attracted interest from the pharmaceutical industry and institutional investors, especially in Europe.

I first attended the 11 th Annual Conference on Alzheimer's disease and Parkinson's disease from March 6-10. The conference provided the opportunity to meet with colleagues from the industry, as well as speak with several opinion leaders who shared their insights with me. A foremost topic of discussion centered on the FDA's new guidelines published in February this year, titled Guidance for Industry Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease. Taken at face value, the new guidelines are encouraging and represent an important departure from the FDA's previous position, in that they are designed to facilitate and accelerate AD drug development. At the same time, several industry experts cautioned against reading too much into the guidelines, stressing that the FDA has yet to ratify its position and will need to consider each New Drug Application on a case-by-case basis.  

The conference comprised several interesting scientific presentations concerning the underlying pathophysiology of AD, as well as the potential of various therapeutic approaches. Not surprisingly, there were a large number of presentations centered on tau protein, which has become regarded as a key neurotoxicity mediator leading to irreversible damage and death of nerve cells. I was encouraged by several examples of assays being developed to evaluate drug compounds targeting tau that could be helpful to Intellect.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs